RESULTS: Forty-nine patients with a median of 4 prior lines of chemotherapy received at least 1 vaccination. Twenty-eight patients completed the 3 vaccination regimen. Six patients received 1 six-month boost after the regimen, and one patient received 7 six-month boosts. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended phase II dose. The most common related toxicity in all patients was injection site reactions (24%). Two patients had a partial response (PR), 14 had stable disease (SD), and 19 had progressive disease (PD). CONCLUSIONS: The study vaccine is safe, exhibits anti-tumor activity and shows preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to monoclonal antibody therapies.
- Received December 7, 2018.
- Revision received January 18, 2019.
- Accepted February 21, 2019
- Forums
- ASX - By Stock
- IMU
- Ann: Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data
Ann: Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data, page-7
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $404.2M |
Open | High | Low | Value | Volume |
5.6¢ | 5.7¢ | 5.5¢ | $379.9K | 6.840M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 1581916 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 680013 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1581916 | 0.055 |
18 | 2110762 | 0.054 |
19 | 3200677 | 0.053 |
21 | 1960514 | 0.052 |
21 | 1582344 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 680013 | 6 |
0.057 | 2073020 | 14 |
0.058 | 213000 | 4 |
0.059 | 492000 | 5 |
0.060 | 1402780 | 14 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |